Autopsy report · NCT06613685
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
Cause of deathFunding or business
“Sponsor decision to terminate study.”
Life of this trial
- Ran for about 1 year 5 months before it stopped.
- 73 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- HIV-1-infection
- Interventions
- lepetegravir; lenacapavir pacfosacil; Bictegravir/emtricitabine/tenofovir alafenamide; lepetegravir/lenacapavir pacfosacil FDC; Placebo to Match BVY; Placebo to Match GS1720/GS-4182 FDC
- Participants
- 73
- Sites
- 58
- Countries
- Canada, Germany, Poland, Portugal, Puerto Rico, Romania, South Africa, Spain, United States
Trials that died the same way
- Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
“Sponsor decision to terminate the study” - Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study” - The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
“Business decision by sponsor to terminate the study” - Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
“Study termination by the Sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.